Setting a new standard in safety.⁵

Engineered for efficiency.

PulseSelect[™]

Pulsed Field Ablation (PFA) System


PulseSelect™

Pulsed Field Ablation System

Setting a new standard in safety⁵

Differentiated system safety features

Developed over 15 years of PFA research



Unmatched safety^{2,3}

Engineered with differentiated safety features from 15 years of PFA research, and backed by the results of one of the safest IDE AF ablation trials to date.²

Consistent efficiency

Rapid, effective PVI² through consistent and predictable energy delivery and catheter maneuverability.

Simplified adaptability³

Seamless transition to PFA with freedom to adapt to your preferred workflow.

Indicated for use in drug refractory, recurrent, symptomatic paroxysmal (PAF) and persistent (PsAF) patients.

Engineered for efficiency

PulseSelect™

Pulsed Field Ablation Loop Catheter

9 electrodes built to sense, ablate, and pace

25 mm diameter loop

9 Fr shaft with bidirectional steering



to produce predictable, consistent, and contiguous energy delivery⁵



 20-degree forward tilt to ensure consistent

uniform tissue contact⁵



Full catheter visualization on existing mapping systems and imaging tools²

Intuitive stepwise approach to PVI†


All pulmonary veins isolated in less than 30 seconds of total energy delivery 3



Over-the-wirefor enhanced stability
and self-centering control



Ostial applications
Stepwise catheter rotation
for overlapping lesions



Antral applications
Stepwise catheter rotation
for overlapping lesions

[†]Operators targeted pulmonary vein isolation using a wide antral approach during PULSED AF procedures.

PULSED AF²

Trial design

Paired single arm. Prospective, non-randomized, Global IDE clinical study.

9 countries41 sites67 operators

67 operators300 PFA subjects

0 Esophageal events

O PV stenosis

O Phrenic nerve injury

O Coronary spasm noted

Total of 13 adverse events measured, resulted in 1 cerebrovascular accident and 1 tamponade.



One of the lowest safety event rates of any atrial fibrillation technology to-date.

Proven efficacy

Freedom from AF/AFL/AT

70% PAF 62% PsAF

Consistent efficiency

Left atrial dwell time **50 minutes or under** when excluding the 20-minute trial-mandated wait period.⁴

65 (± 29) minutes PAF

70 (± 29) minutes PsAF

1st PFA IDE trial completed

Only PFA IDE trial to demonstrate efficacy for both PAF and PsAF patients.

FlexCath Contour™

Steerable Sheath – 10 Fr

Steering therapy with confidence¹



Braided bidirectional shaft design provides catheter support and resistance to kinking¹

Smooth sheath-dilator transition with transseptal crossing indication¹

Robust adjustment knob and rounded handle

Two tip lengths enable alignment with RIPV in difficult anatomies¹





1 Medtronic data on file. 2024.

2 Verma A, Haines DE, Boersma LV, et al. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation. May 9, 2023;147(19):1422-1432.

3 Medtronic data on file. November 2023.

4 Verma A, Boersma L, Haines DE, et al. First-in-Human Experience and Acute Procedural Outcomes Using a Novel Pulsed Field Ablation System: The PULSED AF Pilot Trial. Circ Arrhythm Electrophysiol. January 2022;15(1):e010168.

5 Medtronic data on file.

Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. For further information, please call Medtronic at 1-800-268-5346 and/or consult the Medtronic website at www.medtronic.ca.

Medtronic

99 Hereford Street Brampton, Ontario, L6Y 0R3 Toll-free: 800.268.5346 Tel: 905.460.3800

medtronic.ca

©2024 Medtronic. All rights reserved. Medtronic, Medtronic logo and Engineering the extraordinary are trademarks of Medtronic.

TM*Third party brands are trademarks of their respective owners.
All other brands are trademarks of a Medtronic company.

UC202402764aEC CA-CTL-0295-E Rev. 02/2024